Data / Form D filings / SOLIGENIX, INC.
SOLIGENIX, INC.: Form D filings
SOLIGENIX, INC., a pharmaceuticals company in Princeton, NJ, filed 7 Form D notices with the SEC between 2008 and 2017. The latest, on November 8, 2017, reports $2 million sold of a $2 million offering to 6 investors.
Find out what SOLIGENIX, INC. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 29 EMMONS DRIVE, SUITE C-10, Princeton, NJ, 08540
- Phone
- (609) 538-8200
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 812796
The full lists. Form D filings in New Jersey: 714 rows, $35.70, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 8, 2017 | New notice | $1,964,000 | $1,964,000 | $0 | 6 | Nov 2, 2017 | sec.gov |
| May 3, 2013 | New notice | $1,500,000 | $1,500,000 | $0 | 1 | Apr 27, 2013 | sec.gov |
| Jul 2, 2010 | New notice | $5,904,277 | $5,904,277 | $0 | 46 | Jun 18, 2010 | sec.gov |
| Mar 24, 2009 | New notice | $400,000 | $300,000 | $100,000 | 1 | Mar 6, 2009 | sec.gov |
| Feb 27, 2009 | New notice | $4,500,000 | $4,500,000 | $0 | 1 | Feb 11, 2009 | sec.gov |
| Feb 3, 2009 | New notice | $2,384,200 | $2,384,200 | $0 | 6 | Jan 20, 2009 | sec.gov |
| Dec 5, 2008 | New notice | $1,500,000 | $1,500,000 | $0 | 1 | Dec 1, 2008 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Adam T. Rumage | Executive Officer | |
| Richard C. Straube, MD MSc | Executive Officer | |
| Karen Christopher Krumeich | Executive Officer | |
| Oreola Christopher Donini, PhD | Executive Officer | |
| Keith L. Brownlie, CPA | Director | |
| Jerome B. Zeldis, PhD | Director | |
| Gregg A. LaPointe, CPA | Director | |
| Robert J. Rubin, MD | Director | |
| R. Christopher Cavalli, PhD | Executive Officer | |
| Marco M. Brughera, DVM | Director | |
| Christopher J. Schaber, PhD | Executive Officer, Director |
Other pharmaceuticals companies in New Jersey that filed recently
- Grace Therapeutics, Inc. $10 million · Aug 11, 2026
Every Form D from the week of Nov 6, 2017 · All recent filings in New Jersey · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what SOLIGENIX, INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.